CIK 0001022079 · Large accelerated filer
QUEST DIAGNOSTICS INC
Sign in to watch- Ticker
- DGX
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 161387862
- Phone
- 9735202700
- Business address
- 500 PLAZA DRIVE, SECAUCUS, NJ, 07094
- Former names
- CORNING CLINICAL LABORATORIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,730,307
- in 5 filings, $16.7M under 10b5-1 plans
Net −$16,730,307. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- PREVOZNIK MICHAEL E −$5.5M SVP & General Counsel sold 38% of stake
- Doherty Catherine T. −$5.5M Executive Vice President sold 24% of stake
- Plewman Patrick −$3.0M SVP for Diagnostic Services sold 44% of stake
- Davis J. E. −$2.4M CEO and President sold 8% of stake
- PFEIFFER GARY M −$292K Director sold 4% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-25 | Gregg Vicky B Director | Sale | −1,250 | $191.76 | $240K | 17,037 |
| 2025-11-18 | DELANEY MARK E SVP & Chief Commercial Officer | Option exercise 10b5-1 | +7,846 | $144.47 | $1.1M | 15,376 |
| 2025-11-18 | DELANEY MARK E SVP & Chief Commercial Officer | Option exercise 10b5-1 | +100 | $143.33 | $14K | 15,476 |
| 2025-11-18 | DELANEY MARK E SVP & Chief Commercial Officer | Sale 10b5-1 | −7,946 | $187.35 | $1.5M | 7,530 |
| 2025-11-18 | DELANEY MARK E SVP & Chief Commercial Officer | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −7,846 | $144.47 | $1.1M | 0 |
| 2025-11-18 | DELANEY MARK E SVP & Chief Commercial Officer | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −100 | $143.33 | $14K | 7,484 |
| 2025-11-05 | Davis J. E. CEO and President | Shares withheld for taxes | −7,143 | $175.57 | $1.3M | 120,480 |
| 2025-10-23 | PFEIFFER GARY M Director | Other disposition · Phantom Stock | −4,413.28 | $190.58 | $841K | 0 |
| 2025-10-22 | PFEIFFER GARY M Director | Sale | −1,482 | $182.40 | $270K | 29,431 |
| 2025-10-21 | SAMAD SAM Executive Vice President & CFO | Grant or award | +68 | $189.08 | $13K | 25,741 |
| 2025-10-21 | Plewman Patrick SVP for Diagnostic Services | Grant or award | +46 | $189.08 | $9K | 15,333 |
| 2025-10-21 | KUPPUSAMY KARTHIK SVP, Clinical Solutions | Grant or award | +15 | $189.08 | $3K | 8,379 |
| 2025-10-21 | Gregg Vicky B Director | Grant or award | +70 | $189.08 | $13K | 18,287 |
| 2025-10-21 | DELANEY MARK E SVP & Chief Commercial Officer | Grant or award | +15 | $189.08 | $3K | 7,530 |
| 2025-10-21 | CARTER ROBERT B Director | Grant or award | +6 | $189.09 | $1K | 2,698 |
| 2025-10-01 | RING TIMOTHY M Director | Grant or award · Phantom Stock Units | +233 | 17,036.5 | ||
| 2025-10-01 | Lassiter Wright III Director | Grant or award · Phantom Stock Units | +157 | 678.78 | ||
| 2025-09-26 | PREVOZNIK MICHAEL E SVP & General Counsel | Option exercise 10b5-1 | +227 | $103.57 | $24K | 38,344 |
| 2025-09-26 | PREVOZNIK MICHAEL E SVP & General Counsel | Sale 10b5-1 | −83 | $187.22 | $16K | 38,261 |
| 2025-09-26 | PREVOZNIK MICHAEL E SVP & General Counsel | Sale 10b5-1 | −144 | $188.66 | $27K | 38,117 |
Page 9 of 21 · 409 trades